COM:REVBIOSCIENCES
Revelation Biosciences, Inc.
- Stock
Last Close
0.75
22/11 21:00
Market Cap
2.91M
Beta: -
Volume Today
116.70K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 731.08K - | 575.23K 21.32% | 957.05K 66.38% | |||
average receivables | ||||||
book value per share | -0.42 - | 0.78 285.78% | -0.27 134.48% | 1.95 825.94% | 29.07 1,389.12% | |
capex per share | -0.36 - | |||||
capex to depreciation | -7.86 - | |||||
capex to operating cash flow | 0.01 - | |||||
capex to revenue | ||||||
cash per share | 1.15 - | 3.45 200.44% | 9.75 182.73% | 52.45 438.19% | ||
days of inventory on hand | ||||||
days payables outstanding | 19.82K - | |||||
days sales outstanding | ||||||
debt to assets | 0.01 - | |||||
debt to equity | -0.17 - | |||||
dividend yield | ||||||
earnings yield | -0.00 - | -0.00 116.41% | -0.09 102,292.66% | -3.01 3,216.93% | -0.04 98.84% | |
enterprise value | 88.79M - | 1.53B 1,627.54% | 130.77M 91.47% | -1.67M 101.28% | -8.56M 412.92% | |
enterprise value over ebitda | -24.39K - | -10.54K 56.78% | -10.96 99.90% | 0.15 101.40% | 0.99 544.12% | |
ev to operating cash flow | -7.01K - | -11.79 99.83% | 0.15 101.26% | 1.17 689.79% | ||
ev to sales | ||||||
free cash flow per share | -0.05 - | -30.34 60,581.26% | -20.81 31.41% | -31.87 53.11% | ||
free cash flow yield | -0.00 - | -0.08 59,688.89% | -3.13 3,582.25% | -2.12 32.21% | ||
graham net net | -3.04 - | 0.87 128.68% | -2.34 369.17% | 1.49 163.47% | 28.11 1,789.18% | |
graham number | 1.99 - | 0.74 62.85% | 14.00 1,792.94% | 29.66 111.78% | 18.55 37.46% | |
income quality | 1.60 - | 0.93 42.29% | 1.04 11.97% | 60.59 5,748.54% | ||
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | 286.18 - | 310.75 8.59% | ||||
interest debt per share | -0.07 - | -0.06 4.08% | ||||
inventory turnover | ||||||
invested capital | -0.17 - | |||||
market cap | 88.79M - | 1.54B 1,632.60% | 132.03M 91.42% | 3.58M 97.29% | 3.43M 4.20% | |
net current asset value | -26.31K - | 3.41M 13,067.52% | -229.61K 106.73% | 962.32K 519.11% | 6.51M 576.65% | |
net debt to ebitda | 30.88 - | 0.11 99.66% | 0.48 359.73% | 1.39 186.68% | ||
net income per share | -0.42 - | -0.03 92.57% | -32.41 103,820.91% | -20.03 38.21% | -0.53 97.37% | |
operating cash flow per share | -0.05 - | -29.99 59,867.72% | -20.81 30.59% | -31.87 53.11% | ||
payables turnover | 0.02 - | |||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.16 - | -0.03 81.60% | -5.87 19,781.24% | -1.96 66.58% | -0.01 99.50% | |
revenue per share | ||||||
roe | 1 - | -0.04 104.00% | 120.51 301,493.44% | -10.26 108.51% | -0.02 99.82% | |
roic | 1.00 - | -0.04 104.26% | 181.16 424,902.86% | -10.29 105.68% | -1.30 87.34% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -0.42 - | 0.78 285.78% | -0.27 134.48% | 1.95 825.94% | 29.07 1,389.12% | |
stock based compensation to revenue | ||||||
tangible asset value | -3.64K - | 3.41M 93,877.46% | -99.47K 102.92% | 1.05M 1,158.06% | 6.65M 531.64% | |
tangible book value per share | -0.42 - | 0.78 285.78% | -0.27 134.48% | 1.95 825.94% | 29.07 1,389.12% | |
working capital | -26.31K - | 3.41M 13,067.52% | -229.61K 106.73% | 962.32K 519.11% | 6.51M 576.65% |
All numbers in USD (except ratios and percentages)